Meeting
2020 Gastrointestinal Cancers Symposium
Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC).
Authors
Angel Alsina
Tampa General Hospital, Tampa, FL
Angel Alsina , Masatoshi Kudo , Arndt Vogel , Ann-Lii Cheng , Won Young Tak , Baek-Yeol Ryoo , T.R. Jeffry Evans , Carlos Lopéz Lopéz , Bruno Daniele , Jean-Frédéric Blanc , Min Ren , Rae Lynn Baldwin , Namiki Izumi , Shukui Qin , Richard S. Finn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT01761266
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 520)
Abstract #
520
Poster Bd #
C1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of lenvatinib (LEN) vs sorafenib (SOR) in the first-line (1L) treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC): A post hoc analysis of patients with nonviral etiology from REFLECT.
First Author: Ari David Baron
Poster
2021 Gastrointestinal Cancers Symposium
Post hoc analysis in patients (pts) with unresectable hepatocellular carcinoma (uHCC) who progressed to Child-Pugh B (CPB) liver function in the phase III REFLECT study of lenvatinib (LEN).
First Author: Jasmine Huynh
Poster
2020 Gastrointestinal Cancers Symposium
Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC).
First Author: Arndt Vogel
Poster
2019 Gastrointestinal Cancers Symposium
Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma.
First Author: Angel Alsina